4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plans
As 4D Molecular Therapeutics prepares to shift into a late-stage clinical biotech, it is letting go of a quarter of its staffers and pruning its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
